This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yokoe, T. Articles by Mori, M. Search for Related Content PubMed PubMed Citation Articles by Yokoe, T. Articles by Mori, M.

Efficient Identification of a Novel Cancer/Testis Antigen for Immunotherapy Using Three-Step Microarray Analysis

¹ Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan; ² Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan; ³ Department of Surgery, Jikei University School of Medicine, Minato-ku, Tokyo, Japan; and ⁴ Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Saitama, Japan

Requests for reprints: Masaki Mori, Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu 874-0838, Japan. Phone: 81-977-27-1650; Fax: 81-977-27-1651; E-mail: mmori{at}beppu.kyushu-u.ac.jp.

Key Words: cancer/testis antigen • laser microdissection • cDNA microarray • CTL • immunotherapy

Advanced technology in molecular biology has provided us powerful tools for the diagnosis and treatment for cancer. We herein adopted a new methodology to identify a novel cancer/testis (CT) antigen with high frequency of expression in colorectal cancer as follows: (a) combining laser microdissection and cDNA microarray was used to analyze the gene expression profile of colorectal cancer cells; (b) genes overexpressed in testis and underexpressed in normal colon epithelium were analyzed using cDNA microarray; and (c) the gene expression profile of colorectal cancer cells was compared with that of normal testis. Using this methodology, we selected 38 candidates for CT antigen. Among these genes, we identified a novel CT antigen, serine/threonine kinase 31 (STK31), which was previously reported as a gene expressed in spermatogonia. Reverse transcription–PCR analysis showed that STK31 gene expression levels in cancer samples were significantly higher (P < 0.0001) than those in normal samples. The STK31 gene was frequently expressed not only in colorectal cancer but also in gastric and esophageal cancer. Moreover, STK31 peptide was able to elicit specific CTLs and induced CTLs lysed either peptide-loading or endogenously STK31-expressing target cells. These results showed that the new methodology in this study facilitated identification of CT antigens and that STK31 may be a candidate for cancer immunotherapy against gastrointestinal cancer. [Cancer Res 2008;68(4):1074–82]

This article has been cited by other articles:

				X. Wu, J. A. Schmidt, M. R. Avarbock, J. W. Tobias, C. A. Carlson, T. F. Kolon, J. P. Ginsberg, and R. L. Brinster Prepubertal human spermatogonia and mouse gonocytes share conserved gene expression of germline stem cell regulatory molecules PNAS, December 22, 2009; 106(51): 21672 - 21677. [Abstract] [Full Text] [PDF]